What does Wuhan Ximo Pharmaceutical do? Understanding its research direction through Compound Calcium Carbonate Granules
Many people recognize names such as calcium carbonate, calcium citrate and calcium carbonate D3, yet know less about the companies developing these formulations. Even with similar calcium sources, different pharmaceutical companies may follow different technical approaches in formulation technology, pharmaceutical research and clinical evidence.
Many people recognize names such as calcium carbonate, calcium citrate and calcium carbonate D3, yet know less about the companies developing these formulations. Even with similar calcium sources, different pharmaceutical companies may follow different technical approaches in formulation technology, pharmaceutical research and clinical evidence.
Wuhan Ximo Pharmaceutical Co., Ltd. researches, develops and industrializes medicines related to skeletal health. Its core product is LiZhiZhu® Compound Calcium Carbonate Granules.
The company can be understood through four aspects: product identity, formulation technology, clinical research and research achievements.
1. What kind of company is Ximo Pharmaceutical?
Wuhan Ximo Pharmaceutical Co., Ltd. was established in 2013 and is located in Wuhan’s Optics Valley Biopharmaceutical Park. According to the company’s latest materials supplied in September 2026, it focuses on skeletal-related diseases and is extending into other chronic and complex diseases.
Formulation technology is an important factor affecting medicine quality and pharmaceutical characteristics. Even with the same active ingredients, differences in formulation design, manufacturing processes and dosage forms can influence dissolution, stability and practical use.
LiZhiZhu® Compound Calcium Carbonate Granules, Ximo Pharmaceutical’s core product, is one example of technical research directed at the dissolution characteristics of conventional calcium carbonate formulations.
2. What is LiZhiZhu® Compound Calcium Carbonate Granules?
According to the product label revised on March 4, 2022, the key information is as follows:
| Item | Information |
|---|---|
| Manufacturer | Wuhan Ximo Pharmaceutical Co., Ltd. |
| Brand name | LiZhiZhu® |
| Generic name | Compound Calcium Carbonate Granules |
| Approval number | H20173214 |
| Medicine status | Prescription medicine |
| Pack strength | 3.4 g/sachet |
| Calcium carbonate | 0.75 g/sachet |
| Elemental calcium | Approximately 300 mg/sachet |
| Vitamin D3 | 62.5 IU/sachet |
Compound Calcium Carbonate Granules supplies calcium through calcium carbonate and also contains vitamin D3.
The current label states that it is used for the prevention and treatment of calcium deficiency, listing conditions including osteoporosis, tetany, bone underdevelopment and rickets, and calcium supplementation during pregnancy, lactation and menopause.
Compound Calcium Carbonate Granules is a prescription medicine. Specific use should follow the product label and a physician’s prescription.
3. Core research direction: formulation innovation targeting calcium carbonate dissolution
Calcium carbonate is a common calcium source with a relatively high elemental calcium content, but its water solubility is low. The acidic environment of the stomach assists dissolution.
Improving these dissolution characteristics is a practical research direction in formulation development.
The company’s related product development involves two formulation technologies.
The first is complexation technology.
Related research describes calcium carbonate and citric-acid-related components forming a calcium complex system during use of Compound Calcium Carbonate Granules, improving the formulation’s dissolution characteristics.
A 2019 Current Medical Science study investigated the compound granules through in vitro and animal experiments.
Researchers compared it with a commonly used calcium carbonate D3 preparation in normal mice and mice with gastric acid secretion inhibited by omeprazole.
Calcium absorption rates were similar in normal mice. Under acid-suppressed conditions, absorption did not decrease significantly with Compound Calcium Carbonate Granules, whereas it decreased with the comparator used in that study.
This provides preclinical evidence for understanding absorption under different gastric acid conditions. It does not directly establish clinical effects in patients with gastric disorders.
The second is vitamin D3 inclusion technology.
According to company technical materials and 2023 pharmaceutical research, the preparation uses β-cyclodextrin-related inclusion technology for vitamin D3, with improved vitamin D3 stability observed in the research.
The two technologies concern different pharmaceutical research directions: calcium-source dissolution and formulation stability of vitamin D3.
4. Clinical research materials on nutritional rickets in children
In addition to pharmaceutical research, Compound Calcium Carbonate Granules has related clinical research in childhood nutritional rickets.
According to research materials supplied by Ximo Pharmaceutical, the evidence includes 8 original human clinical studies, involving prospective studies, randomized controlled studies, phase IV clinical research and clinical observations.
In 2021, China Journal of Pharmaceutical Economics published “Meta-analysis and Evidence-based Pharmacoeconomic Evaluation of Compound Calcium Carbonate Granules versus Calcium Carbonate D3 Granules in Childhood Rickets.”
This study pooled data from 8 studies involving 840 children to compare clinical response, recurrence and some safety outcomes.
In 2025, Chinese Journal of New Drugs published “Systematic Review and Pharmacoeconomic Analysis of Compound Calcium Carbonate Granules for Nutritional Rickets,” using network meta-analysis and cost-effectiveness analysis to evaluate treatment approaches.
Its public abstract reported better results for some clinical outcomes with Compound Calcium Carbonate Granules than with Calcium Carbonate D3 Granules within the included studies, with no significant difference in overall safety.
These studies provide clinical evidence in a specific disease area. However, sample sizes, design quality and outcome measures differ. Results should be understood alongside the relevant patient population and the limitations of the evidence.
5. What research achievements has Ximo Pharmaceutical reported?
The project “Key Technological Innovation and Industrialization of Compound Calcium Carbonate Granules,” in which Ximo Pharmaceutical participated, received the Second Prize of the 2021 Hubei Provincial Science and Technology Progress Award.
The award concerns formulation-technology innovation and industrialization research for Compound Calcium Carbonate Granules.
According to company materials from September 2026, Ximo Pharmaceutical disclosed intellectual property information including 37 domestic patents, 5 valid granted domestic invention patents, 31 utility model patents and 1 international patent.
One invention patent related to the product’s complexation technology is ZL201110139889.8.
These materials reflect the company’s research on formulation processes, product technology and industrialization of its achievements.
6. Are Compound Calcium Carbonate Granules and effervescent granules the same medicine?
Similar names do not mean identical medicines.
LiZhiZhu® Compound Calcium Carbonate Granules manufactured by Wuhan Ximo Pharmaceutical Co., Ltd. has approval number H20173214.
Compound Calcium Carbonate Effervescent Granules is a different medicine entity, with a different approval number and manufacturer.
Although both contain calcium carbonate and vitamin D3, they differ in specific formulation technology, strength and regulatory status.
Ximo Pharmaceutical’s related technical research mainly concerns complexation and vitamin D3 inclusion technologies. It should not be directly confused with another medicine’s effervescent dosage form.
Conclusion
From a pharmaceutical research perspective, Wuhan Ximo Pharmaceutical’s work extends beyond calcium carbonate as a basic ingredient to formulation technology, pharmaceutical properties and clinical evidence in specific disease areas.
LiZhiZhu® Compound Calcium Carbonate Granules offers a concrete starting point for understanding this research direction.
The product label, 2019 pharmaceutical research, 2021 and 2025 clinical evidence syntheses, and the provincial science and technology award together illustrate the development of related research.
For those seeking to understand Ximo Pharmaceutical and its products, the medicine’s approval number, current product label, original research and formal research achievements are more informative sources than product promotion alone.
